A groundbreaking new drug candidate, developed by Espervita Therapeutics, has shown remarkable promise in preclinical studies conducted at McMaster University. This novel therapy, named EVT0185, has the potential to revolutionize the treatment of metabolic liver disease and fibrosis, offering hope to the millions affected by these conditions. The research, led by Professor Greg Steinberg, highlights a critical gap in current medical options, as there are no approved drugs in Canada to treat metabolic dysfunction-associated steatohepatitis (MASH), a disease often linked to obesity and type 2 diabetes.
Liver fibrosis, a late-stage symptom of MASH, is a serious concern as it can lead to cancer, heart attacks, and strokes. Current treatments primarily focus on lifestyle changes and a Mediterranean diet, but these interventions fall short in reversing existing liver damage. Steinberg emphasizes the need for more effective therapies, especially given the limited options available.
The drug candidate, EVT0185, developed in collaboration with Espervita Therapeutics, has demonstrated powerful curative and restorative effects in disease models. It targets two critical enzymes, ACLY and ACSS2, to control fat synthesis and burning, effectively preventing harmful matter from accumulating in the liver and bloodstream. This multi-use compound is set to advance into clinical trials by 2027, following further preclinical and toxicology assessments.
The research partnership between McMaster and Espervita Therapeutics has yielded significant findings, including the compound's potential as a treatment for liver cancer, as previously reported in the journal Nature. Now, the focus shifts to its role in addressing the unmet need for agents that reduce liver fibrosis and improve blood glucose and cholesterol levels. Steinberg believes this drug candidate could transform the treatment of liver disease, potentially preventing complications like liver cancer, diabetes, and heart disease.
